BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16418875)

  • 1. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
    Jensen SA; Sørensen JB
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
    Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Deboever G; Hiltrop N; Cool M; Lambrecht G
    Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine cardiotoxicity--case reports and literature review.
    Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
    Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
    Saif MW; Garcon MC; Rodriguez G; Rodriguez T
    In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
    Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic cardiotoxicity associated with 5-fluorouracil.
    Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
    Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-related cardiotoxicity: recognition and management.
    Saif MW; Tomita M; Ledbetter L; Diasio RB
    J Support Oncol; 2008 Jan; 6(1):41-8. PubMed ID: 18257400
    [No Abstract]   [Full Text] [Related]  

  • 9. Capecitabine induced cardiotoxicity: a case report and review of literature.
    Tunio MA; Hashmi A; Shoaib M
    Pak J Pharm Sci; 2012 Jan; 25(1):277-81. PubMed ID: 22186341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
    Shaib W; Lee V; Saif MW
    In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
    Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
    Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
    Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
    Chu E; Shi N; Wei W; Bendell JC; Cartwright T
    Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiotoxicity of 5-fluorouracil].
    Teixeira L; Barry S; Debourdeau P; Cohen A; Tournigand C
    Bull Cancer; 2004 Nov; 91 Suppl 3():154-8. PubMed ID: 15899622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
    Jhaveri KD; Flombaum C; Shah M; Latcha S
    J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
    Shah NR; Shah A; Rather A
    J Oncol Pharm Pract; 2012 Mar; 18(1):132-5. PubMed ID: 21321041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.